You are using an older browser version. Please use a supported version for the best MSN experience.

Serum Institute resumes COVAX exports to help with vaccine equity

New York Daily News logo New York Daily News 11/26/2021 Jami Ganz

India’s Serum Institute on Friday restarted its exports of coronavirus vaccines to the UN-supported COVAX program after the country was devastated by the delta-fueled surge earlier this year.

Plans for the company to be the distribution program’s primary supplier — which included distributing 200 million doses of the AstraZeneca shot — were disrupted during the devastating uptick of cases, The Associated Press reports.

Prior to the halt, the Serum Institute of India also had agreements, which had yet to be finalized, to supply an additional 350 million doses.

Employees pack boxes containing vials of Covishield, a version of the AstraZeneca vaccine, at the Serum Institute of India on Monday. © Provided by New York Daily News Employees pack boxes containing vials of Covishield, a version of the AstraZeneca vaccine, at the Serum Institute of India on Monday.

Employees pack boxes containing vials of Covishield, a version of the AstraZeneca vaccine, at the Serum Institute of India on Monday.

Tajikistan will be the first recipient under the new COVAX program, with doses set to depart for the Central Asian country Friday evening, according to a statement from the Serum Institute.


Video: Australia joins diplomatic boycott of Beijing Winter Games (Reuters)

The company had fulfilled just under 30 million of those doses to COVAX when such operations were put on pause, according to vaccine alliance GAVI.

A container truck carrying a consignment of vaccines for Nepal is seen at Serum Institute of India. © Provided by New York Daily News A container truck carrying a consignment of vaccines for Nepal is seen at Serum Institute of India.

A container truck carrying a consignment of vaccines for Nepal is seen at Serum Institute of India.

The program, which is co-managed by GAVI, was intended to help level the inequalities among different countries’ vaccination accessibility.

The company, which has already produced over 1 billion AstraZeneca doses under license — nearly all for use in India — is optimistic its exports will see a significant uptick with the onset of the new year.

The company this summer also begun making the Novavax vaccine under license. That shot has been approved in Indonesia and the Philippines and, due to lower maintenance storage needs, could help to increase vaccine equity around the globe.

With News Wire Services

AdChoices
AdChoices

More from New York Daily News

New York Daily News
New York Daily News
image beaconimage beaconimage beacon